Dr. Sunil A. Reddy
Claim this profileStanford Cancer Institute Palo Alto
Studies Melanoma
Studies Skin Cancer
10 reported clinical trials
14 drugs studied
Area of expertise
1Melanoma
Stage IV
Stage III
PD-1
2Skin Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Sunil A. Reddy is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Ultrasound Techniques
for Detecting Immunotherapy Response in Solid Tumors
Primary objective is to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by CEUS, can predict initial objective response to therapy, defined by current standard-of-care Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Recruiting1 award N/A
More about Sunil A. Reddy
Clinical Trial Related8 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sunil A. Reddy has experience with
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Doppler Ultrasound
- Long Ensemble Angular-coherence Doppler [LEAD] Ultrasound
- Contrast-enhanced Ultrasound (CEUS)
Breakdown of trials Sunil A. Reddy has run
Melanoma
Skin Cancer
Uveal Melanoma
Cutaneous Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sunil A. Reddy specialize in?
Sunil A. Reddy focuses on Melanoma and Skin Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are Stage III.
Is Sunil A. Reddy currently recruiting for clinical trials?
Yes, Sunil A. Reddy is currently recruiting for 4 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that Sunil A. Reddy has studied deeply?
Yes, Sunil A. Reddy has studied treatments such as Nivolumab, Ipilimumab, Pembrolizumab.
What is the best way to schedule an appointment with Sunil A. Reddy?
Apply for one of the trials that Sunil A. Reddy is conducting.
What is the office address of Sunil A. Reddy?
The office of Sunil A. Reddy is located at: Stanford Cancer Institute Palo Alto, Palo Alto, California 94304 United States. This is the address for their practice at the Stanford Cancer Institute Palo Alto.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.